Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

被引：0
|
作者：
Ring, Alistair E.
Moretti, Laura
Afshari-Mehr, Angelica
Wardley, Andrew M.
Kilburn, Lucy
Gurel, Bora
MacPherson, Iain R.
Baird, Richard D.
Martin, Sue
Pearson, Alex
Roylance, Rebecca
Winter, Matthew
Dunne, Kathryn
Copson, Ellen
Hickish, Tamas
Stephens, Peter
Burcombe, Russell J.
Randle, Katrina
Bliss, Judith
Turner, Nicholas C.
机构：
[1] Royal Marsden NHS Fdn Trust, Surrey, England
[2] Inst Canc Res, Clin Trials & Stat Unit, London, England
[3] Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, London, England
[4] Outreach Res & Innovat Grp, Manchester, England
[5] Inst Canc Res, London, England
[6] Beatson West Scotland Canc Ctr, Glasgow, Scotland
[7] Canc Res UK, Cambridge Ctr, Cambridge, England
[8] Univ Coll London Hosp NHS Fdn Trust, London, England
[9] Univ Coll London Hosp, Biomed Res Ctr, NIHR, London, England
[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England
[11] Royal Marsden Hosp, Ralph Lauren Ctr Breast Canc Res, London, England
[12] Univ Southampton, Southampton, England
[13] Royal Bournemouth Hosp, Bournemouth, England
[14] Poole Gen Hosp, Bournemouth, England
[15] Royal Devon & Exeter Hosp, Exeter, England
[16] Maidstone & Tunbridge Wells NHS Trust, Maidstone, Kent, England
[17] Independent Canc Patients Voice, London, England
[18] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1024
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
    Yuan, Yuan
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Frankel, Paul H.
    Ruel, Christopher
    Schmolze, Daniel
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Stewart, Daphne
    Waisman, James
    Kruper, Laura
    Jones, Veronica
    Menicucci, Andrea
    Uygun, Sahra
    Yoder, Erin
    van der Baan, Bastiaan
    Yim, John H.
    Yeon, Christina
    Somlo, George
    Mortimer, Joanne
    ONCOLOGIST, 2021, 26 (03): : E382 - E393
  • [32] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J. A.
    Novik, Y.
    Speyer, J. L.
    Adams, S.
    Meyers, M. I.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Davis, S.
    Choi, H.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [33] A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I
    Yasojima, Hiroyuki
    Yamamoto, Harukaze
    Masuda, Norikazu
    Aogi, Kenjiro
    Takahashi, Masato
    Yonemori, Kan
    Takeuchi, Masahiro
    Hamada, Akinobu
    Tamura, Kenji
    Sukigara, Tamie
    Nagasaka, Ritsuko
    Nakano, Rie
    Tsujimoto, Yukie
    Morioka, Yuka
    Higuchi, Kiyomi
    Fujiwara, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Preliminary safety and efficacy results of camrelizumab in combination with apatinib and eribulin in heavily pretreated patients with advanced triple-negative breast cancer: A phase II trial
    Liu, Jieqiong
    Tian, Zhenluan
    Wang, Ying
    Lin, Ying
    Li, Hengyu
    CANCER RESEARCH, 2022, 82 (04)
  • [35] TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer
    Zhang, Huiqiang
    Jin, Xiao
    Bian, Li
    TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
  • [36] Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study
    Chung, Hyun Cheol
    Saada-Bouzid, Esma
    Longo, Federico
    Yanez, Eduardo
    Im, Seock-Ah
    Castanon, Eduardo
    Desautels, Danielle N.
    Graham, Donna M.
    Garcia-Corbacho, Javier
    Lopez, Juanita
    Dutcus, Corina
    Okpara, Chinyere E.
    Ghori, Razi
    Jin, Fan
    Groisberg, Roman
    Korakis, Iphigenie
    CANCER, 2024, 130 (19) : 3278 - 3288
  • [37] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Denise A. Yardley
    Dianna L. Shipley
    Nancy W. Peacock
    Mythili Shastry
    Rajiv Midha
    Victor M. Priego
    John D. Hainsworth
    Breast Cancer Research and Treatment, 2015, 152 : 557 - 567
  • [38] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [39] Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer
    Yardley, Denise A.
    Shipley, Dianna L.
    Peacock, Nancy W.
    Shastry, Mythili
    Midha, Rajiv
    Priego, Victor M.
    Hainsworth, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 557 - 567
  • [40] Phase II Trial of RAD001 Plus Carboplatin in Patients with Triple-Negative Metastatic Breast Cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J.
    Novik, Y.
    Speyer, J.
    Adams, S.
    Meyers, M.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Omene, C.
    Choi, H.
    Davis, S.
    Goldberg, J.
    Tiersten, A.
    CANCER RESEARCH, 2011, 71
12345